RGNX Healthcare

REGENXBIO Inc.

$7.63+6.56%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 503.7M USD
Enterprise value: 643.3M USD
Full-time employees: 371

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.93 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (3.49× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.93 vs peers 0.63) and more debt vs equity (3.49× vs peers 0.22×)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 52% from December 2022 to July 2026.
REGENXBIO had 52% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.REGENXBIO had 52% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Much more borrowing than peers. Debt is 3.5× equity vs a peer median of 0.2×.Debt is 3.5× equity vs peers 0.2×.
Debt is 3.5× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 3.5× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Stock-based pay is a large cost. Stock pay was 20% of revenue in 2025.
REGENXBIO paid employees $35M in stock in 2025, 20% of its $170M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, REGENXBIO looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

24/ 100

Oct 5 24 → Nov 4 24

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 27.7% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-39.0%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-23.1%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-49.6%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield14.2%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

69/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 98.7%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth21.6%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 1.88Sector median: 0.0584 · MAD: 0.0840

Revenue growth12.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.61Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

10/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-94.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -8.31Sector median: 0.0706 · MAD: 0.1217

Return on assets-50.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -9.78Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-367.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin-44.9%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-273.7%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 7 → 8

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.93

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -0.91Sector median: 0.6250 · MAD: 0.3380

Current ratio2.86×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.20Sector median: 2.5860 · MAD: 1.3850

Debt / equity3.49×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about REGENXBIO

Is REGENXBIO getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: share count up 27.7%. Its overall score is unchanged at 24/100 since Oct 28, 2026.
How is REGENXBIO valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -39.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -39.0% vs peers 1.5% (weaker than 100% of peers).
Is REGENXBIO growing?: Yes, faster than most of its peers. Growth scores 69/100 against 1,393 healthcare peers. 3-year revenue growth 21.6% vs a peer median of 5.8% (stronger than 82% of peers).3-year revenue growth 21.6% vs peers 5.8% (stronger than 82% of peers).
How profitable is REGENXBIO?: Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on invested capital -367.6% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -367.6% vs peers 4.7% (weaker than 100% of peers).
How risky is REGENXBIO?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 3.49× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 3.49× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 27.7% (existing holders diluted)

Worth watching: REGENXBIO is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	87.8M USD	174.5M USD	+98.7%
Net income (12 months)	−290.0M USD	−196.4M USD	−32.3%
Operating margin	-292.3%	-94.1%	+198.2 pts
Free cash flow (12 months)	−236.4M USD	−249.7M USD	+5.6%
Cash	15.2M USD	36.5M USD	+139.6%
Shares outstanding	51.7M	66.0M	+27.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	89.0%	51.6%	58.8%	59.7%	—	—
Operating margin	34.0%	-233.2%	-297.1%	-280.0%	-94.6%	▲ 185 pts
Net margin	27.2%	-248.7%	-292.0%	-272.5%	-113.8%	▲ 159 pts
Return on assets (ROA)	11.5%	-33.6%	-45.9%	-48.7%	-42.8%	▲ 5.9 pts
Return on equity (ROE)	16.7%	-54.3%	-84.5%	-87.5%	-188.7%	▼ 101 pts
Free cash flow margin	28.6%	-211.3%	-253.1%	-210.7%	-74.1%	▲ 137 pts
Current ratio	3.98×	3.19×	2.57×	2.69×	2.38×	▼ 12%
Interest coverage	6.09×	-11.30×	-39.07×	-18.43×	-3.58×	▲ 81%

RGNX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.93 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (3.49× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.93 vs peers 0.63) and more debt vs equity (3.49× vs peers 0.22×)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 52% from December 2022 to July 2026.

REGENXBIO had 52% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.REGENXBIO had 52% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Much more borrowing than peers. Debt is 3.5× equity vs a peer median of 0.2×.Debt is 3.5× equity vs peers 0.2×.

Debt is 3.5× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 3.5× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.

Stock-based pay is a large cost. Stock pay was 20% of revenue in 2025.

REGENXBIO paid employees $35M in stock in 2025, 20% of its $170M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, REGENXBIO looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about REGENXBIO

Is REGENXBIO getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: share count up 27.7%. Its overall score is unchanged at 24/100 since Oct 28, 2026.

How is REGENXBIO valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -39.0% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -39.0% vs peers 1.5% (weaker than 100% of peers).

Is REGENXBIO growing?

Yes, faster than most of its peers. Growth scores 69/100 against 1,393 healthcare peers. 3-year revenue growth 21.6% vs a peer median of 5.8% (stronger than 82% of peers).3-year revenue growth 21.6% vs peers 5.8% (stronger than 82% of peers).

How profitable is REGENXBIO?

Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on invested capital -367.6% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -367.6% vs peers 4.7% (weaker than 100% of peers).

How risky is REGENXBIO?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 3.49× vs a peer median of 0.22× (weaker than 100% of peers).Debt / equity 3.49× vs peers 0.22× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

87.8M USD

174.5M USD

+98.7%

Net income (12 months)

−290.0M USD

−196.4M USD

−32.3%

Operating margin

-292.3%

-94.1%

+198.2 pts

Free cash flow (12 months)

−236.4M USD

−249.7M USD

+5.6%

Cash

15.2M USD

36.5M USD

+139.6%

Shares outstanding

51.7M

66.0M

+27.7%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

89.0%

51.6%

58.8%

59.7%

—

Operating margin

34.0%

-233.2%

-297.1%

-280.0%

-94.6%

▲ 185 pts

Net margin

27.2%

-248.7%

-292.0%

-272.5%

-113.8%

▲ 159 pts

Return on assets (ROA)

11.5%

-33.6%

-45.9%

-48.7%

-42.8%

▲ 5.9 pts

Return on equity (ROE)

16.7%

-54.3%

-84.5%

-87.5%

-188.7%

▼ 101 pts

Free cash flow margin

28.6%

-211.3%

-253.1%

-210.7%

-74.1%

▲ 137 pts

Current ratio

3.98×

3.19×

2.57×

2.69×

2.38×

▼ 12%

Interest coverage

6.09×

-11.30×

-39.07×

-18.43×

-3.58×

▲ 81%